{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:19Z","timestamp":1789726399591,"version":"4.0.1"},"reference-count":21,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Steven\u2013Johnson syndrome (SJS) is a serious mucocutaneous reaction, characterized by fever, influenza-like symptoms and followed by dermatological manifestations. Capecitabine is an oral fluoropyrimidine carbamate analogue of 5-Fluorouracil (5-FU). It is widely accepted for many malignancies because of its better safety profile and tolerability. Hand-foot syndrome is the common dermatological toxicity associated with Capecitabine and SJS is the rarest manifestation. Case presentation: We report a case of Capecitabine induced SJS in a 70\u2009years old male patient with metastatic carcinoma pancreas. He was treated with intravenous Gemcitabine and Carboplatin initially and then switched to oral therapy with Capecitabine 1000\u2009mg twice daily. After ten days of treatment with Capecitabine, he developed vomiting, mucositis, hyperpigmentation, itching and scrotal mucosal peeling. The clinical status of the patient was suggestive of SJS, which was confirmed by dermatologic consultation. According to Naranjo, WHO-UMC, and Hartwig\u2019s scale, the reaction was found to be probable and severe. Pharmacological as well as supportive care measures were provided, but the condition progressively worsened, and the patient was deceased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Capecitabine can cause severe hypersensitivity reactions which can be dangerous and life-threatening. Health care providers must be aware of all rare adverse effects, including SJS. Clinicians and clinical pharmacists should educate and counsel the patients regarding the likely adverse effects of their chemo drugs because the early identification of toxic symptoms is crucial to reduce further complications to the patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211027945","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:45:31Z","timestamp":1624506331000},"page":"250-254","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Capecitabine induced Steven\u2013Johnson syndrome: A rare case report"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-8280","authenticated-orcid":false,"given":"Kavya","family":"Karthikeyan","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, St. Joseph\u2019s College of Pharmacy, Alappuzha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K V","family":"Sameera","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, St. Joseph\u2019s College of Pharmacy, Alappuzha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintu","family":"Shaji","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, St. Joseph\u2019s College of Pharmacy, Alappuzha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Ann C","family":"Swetha","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lourdes Hospital, Kochi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C S","family":"Madhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lourdes Hospital, Kochi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"bibr1-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1993.01680220104023"},{"key":"bibr2-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00035-2"},{"key":"bibr3-10781552211027945","doi-asserted-by":"publisher","DOI":"10.2165\/11593240-000000000-00000"},{"key":"bibr4-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.510"},{"key":"bibr5-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5701033"},{"key":"bibr6-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5376476"},{"key":"bibr7-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220954900"},{"key":"bibr8-10781552211027945","unstructured":"Chu E, DeVitaJr VT.\n                      Physician\u2019s cancer chemotherapy drug manual 2015\n                      . 15th ed. Jones & Bartlett Learning, 2014, pp. 82\u201387."},{"key":"bibr9-10781552211027945","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140020-00002"},{"key":"bibr10-10781552211027945","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v2.i8.311"},{"key":"bibr11-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf089"},{"key":"bibr12-10781552211027945","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3289"},{"key":"bibr13-10781552211027945","doi-asserted-by":"publisher","DOI":"10.17795\/ijcp-4211"},{"key":"bibr14-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.08.001"},{"key":"bibr15-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2007.11.005"},{"key":"bibr16-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-016-9916-3"},{"key":"bibr17-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.10.013"},{"key":"bibr18-10781552211027945","first-page":"69","volume":"38","author":"Dugan SE.","year":"2013","journal-title":"US Pharm"},{"key":"bibr19-10781552211027945","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.81865"},{"key":"bibr20-10781552211027945","first-page":"11","volume":"29","author":"Vanessa N","year":"2014","journal-title":"Dermnet NZ"},{"key":"bibr21-10781552211027945","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.11.023"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211027945","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211027945","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211027945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:09Z","timestamp":1777688709000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211027945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1177\/10781552211027945"],"URL":"https:\/\/doi.org\/10.1177\/10781552211027945","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]}}}